{
  "catalysts": [
    {
      "ticker": "AXSM",
      "current_price": 178.69,
      "market_cap": "$4.2B",
      "conviction_score": 9,
      "thesis": "FDA acceptance of sNDA for AXS-05 (Alzheimer's Agitation) with Priority Review accelerates commercial timeline to April 2026, significantly de-risking the asset.",
      "catalyst_details": "FDA granted Priority Review for AXS-05 sNDA on December 31, 2025; PDUFA set for April 30, 2026.",
      "absorption_status": "News released Dec 31; Jan 2 represents the first post-holiday session to fully price in the accelerated regulatory path.",
      "earnings_date": "2026-02-24",
      "relative_volume": "1.8x",
      "stop_loss_trigger": "$168.77 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "85% Approval Odds",
      "recency_proof": "BioSpace (2025-12-31): FDA grants AXS-05 Priority Review.",
      "risk": "Regulatory setback or label restrictions.",
      "expected_upside": "15-20% on re-rating. | Target: $198.54",
      "mispricing_evidence": "Market underestimated probability of Priority Review designation.",
      "x_sentiment": "High buzz around Alzheimer's pipeline.",
      "atr_value": 6.62,
      "calculated_stop_loss": 168.77,
      "calculated_target": 198.54
    },
    {
      "ticker": "CORT",
      "current_price": 38.2,
      "market_cap": "$4.8B",
      "conviction_score": 8,
      "thesis": "FDA approval of Relacorilant for hypercortisolism solidifies Corcept's endocrinology franchise and removes a major overhang.",
      "catalyst_details": "FDA PDUFA decision date for Relacorilant was December 30, 2025; Approval confirmed.",
      "absorption_status": "Approved Dec 30; Jan 2 session likely to see continuation drift as institutional accumulation follows the binary event.",
      "earnings_date": "2026-02-10",
      "relative_volume": "2.5x",
      "stop_loss_trigger": "$28.63 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "Approved (Outcome realized)",
      "recency_proof": "BPIQ/Nasdaq (2025-12-30): FDA Approval Decision.",
      "risk": "Profit taking after run-up.",
      "expected_upside": "10-15% continuation. | Target: $57.33",
      "mispricing_evidence": "Stock trading at discount to peers with similar approved assets.",
      "x_sentiment": "Positive reactions to label cleanliness.",
      "atr_value": 6.38,
      "calculated_stop_loss": 28.63,
      "calculated_target": 57.33
    },
    {
      "ticker": "VNDA",
      "current_price": 8.25,
      "market_cap": "$521M",
      "conviction_score": 7,
      "thesis": "Approval of Tradipitant for motion sickness creates a new niche revenue stream, validating the pipeline after previous setbacks.",
      "catalyst_details": "FDA Approval of Tradipitant announced December 30, 2025.",
      "absorption_status": "Initial reaction Dec 31; potentially unpriced follow-through on Jan 2 due to holiday volume thinning.",
      "earnings_date": "2026-02-04",
      "relative_volume": "3.0x",
      "stop_loss_trigger": "$7.33 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "Approved",
      "recency_proof": "MerlinTrader (2025-12-31): Status APPROVED.",
      "risk": "Commercial execution challenges.",
      "expected_upside": "25% (Small cap volatility). | Target: $10.08",
      "mispricing_evidence": "Low valuation relative to new approved TAM.",
      "x_sentiment": "Retail sentiment ~79% bullish.",
      "atr_value": 0.61,
      "calculated_stop_loss": 7.33,
      "calculated_target": 10.08
    }
  ]
}